Latest Europe News

Trigg Minerals has initiated the process for a Nasdaq dual listing via an American Depositary Receipt program, aiming to tap into the world’s largest capital market. The company also raised A$2.5 million from Tribeca Investment Partners, reinforcing its growth strategy.

James Hardie confirms key board changes and underscores its commitment to shareholder value amid strong integration progress with AZEK.

OncoSil Medical reports a remarkable 917% increase in quarterly cash receipts alongside promising clinical trial results and key European market entries, signaling robust momentum in its pancreatic cancer treatment rollout.

Camplify Holdings reports a modest dip in revenue and transaction value due to poor weather, while maintaining positive cash flow and advancing its NSW TAP program rollout.

Ava Risk Group reported a solid start to FY2026 with $9 million in Q1 sales orders and a $7.5 million backlog, underpinning its guidance for a profitable first half.

Clever Culture Systems reports a cashflow positive quarter, expanding its pharmaceutical customer base and launching a new contact plate analysis module that promises to drive recurring revenues.

Arovella Therapeutics reported solid progress in Q1 FY26, moving closer to initiating its first-in-human trial for ALA-101 while securing key patents and maintaining a strong cash position.

Kuniko Limited has executed a binding earn-in agreement for a major Australian gold-silver project and raised A$2.7 million to fund exploration, while progressing its Norwegian battery metals portfolio.

Novonix Limited has achieved its first mass production of industrial-grade synthetic graphite and secured significant funding, advancing its position in North America's battery materials supply chain.

CurveBeam AI reports a 33% rise in device purchase orders and secures a $6.5 million placement alongside a landmark China distribution partnership. The company advances FDA regulatory milestones and establishes a vendor financing facility to boost sales.

Bioxyne Limited has reported a record quarterly revenue of A$14.1 million for Q1 FY26, driven by strong demand in Europe and Australia, alongside a strategic dual listing on the Frankfurt Stock Exchange.

SomnoMed reports a strong start to FY26 with 13.5% revenue growth and confirms the Clayton Sleep Institute as the first US site for its pivotal Rest Assure clinical study, backed by FDA protocol agreement.